Steven Cohen's UTHR Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 99,784 shares of United Therapeutics Corporation (UTHR) worth $41.83 M, representing 0.07% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in UTHR, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2019, adding 325,797 shares. Largest reduction occurred in Q3 2021, reducing 345,500 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's United Therapeutics Corporation (UTHR) Holding Value Over Time
Track share changes against reported price movement
Quarterly United Therapeutics Corporation (UTHR) Trades by Steven Cohen
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +8,700 | New Buy | 8,700 | $128.62 |
| Q4 2014 | -8,700 | Sold Out | 8,700 | $0.00 |
| Q4 2017 | +191,999 | New Buy | 191,999 | $147.95 |
| Q1 2018 | -187,887 | Reduce 97.86% | 4,112 | $112.35 |
| Q2 2018 | -1,336 | Reduce 32.49% | 2,776 | $113.11 |
| Q3 2018 | -2,776 | Sold Out | 2,776 | $0.00 |
| Q4 2018 | +133,643 | New Buy | 133,643 | $108.90 |
| Q1 2019 | -133,643 | Sold Out | 133,643 | $0.00 |
| Q2 2019 | +459,440 | New Buy | 459,440 | $78.06 |
| Q3 2019 | +180,803 | Add 39.35% | 640,243 | $79.75 |
| Q4 2019 | -640,243 | Sold Out | 640,243 | $0.00 |
| Q1 2020 | +579,148 | New Buy | 579,148 | $94.83 |
| Q2 2020 | -309,839 | Reduce 53.50% | 269,309 | $121.00 |
| Q3 2020 | +171,218 | Add 63.58% | 440,527 | $101.00 |
| Q4 2020 | -97,326 | Reduce 22.09% | 343,201 | $151.79 |
| Q1 2021 | -343,201 | Sold Out | 343,201 | $0.00 |
| Q2 2021 | +552,400 | New Buy | 552,400 | $179.41 |
| Q3 2021 | -345,500 | Reduce 62.55% | 206,900 | $184.58 |
| Q4 2021 | +300 | Add 0.14% | 207,200 | $216.08 |
| Q1 2022 | -10,100 | Reduce 4.87% | 197,100 | $179.41 |
| Q2 2022 | -177,285 | Reduce 89.95% | 19,815 | $235.63 |
| Q3 2022 | -19,815 | Sold Out | 19,815 | $0.00 |
| Q2 2023 | +11,900 | New Buy | 11,900 | $220.75 |
| Q3 2023 | -10,863 | Reduce 91.29% | 1,037 | $225.87 |
| Q4 2023 | -1,037 | Sold Out | 1,037 | $0.00 |
| Q1 2024 | +162,700 | New Buy | 162,700 | $229.72 |
| Q2 2024 | -162,700 | Sold Out | 162,700 | $0.00 |
| Q3 2025 | +99,784 | New Buy | 99,784 | $419.21 |
Steven Cohen's United Therapeutics Corporation Investment FAQs
Steven Cohen first purchased United Therapeutics Corporation (UTHR) in Q3 2014, acquiring 8,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held United Therapeutics Corporation (UTHR) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's largest addition to United Therapeutics Corporation (UTHR) was in Q1 2020, adding 579,148 shares worth $54.92 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Steven Cohen's firm, Point72 Asset Management, L.P., owns 99,784 shares of United Therapeutics Corporation (UTHR), valued at approximately $41.83 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, United Therapeutics Corporation (UTHR) represents approximately 0.07% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen's peak holding in United Therapeutics Corporation (UTHR) was 640,243 shares, as reported at the end of Q3 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.